| SutroVax–Roche: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Roche Venture Fund |
2020-03-26 |
| SutroVax–SEVERAL: investment, 202003 financing round Series D $110m co-led by new investors RA Capital + Janus Henderson |
2020-03-26 |
| Roche–Forge Therapeutics: antibiotics, 202003– collab research + license option up to $190.5m for FG-LpxC LUNG program for lung infections |
2020-03-25 |
| Immunogenesis–Minapharm: biopharma production, 202003– supply €na cell line + process developm + production of I-O-candidate by ProBiogen AG |
2020-03-24 |
| Bayer–Curadev: STING agonists, 202003– collab research + license agreem incl upfront payment + €250m milestones + single-digit royalties |
2020-03-23 |
| DeepSee project–Germany (govt): grant, 202003– funding from BMWi (ZIM) + Enterprise Singapore for single cell analysis for cancer drug r+d |
2020-03-23 |
| DeepSee project–Proteona: single cell analysis, 202003– collab project partner AI-driven multi-omics single cell analysis for cancer drug r+d |
2020-03-23 |
| DeepSee project–Singapore (govt): grant, 202003– funding from Enterprise Singapore + German BMWi for single cell analysis for cancer drug r+d |
2020-03-23 |
| DeepSee project–Synovo: single cell analysis, 202003– collab project partner AI-driven multi-omics single cell analysis for cancer drug r+d |
2020-03-23 |
| DeepSee project–Univ Tübingen: single cell analysis, 202003– collab NMI project partner AI-driven multi-omics single cell analysis for cancer drug r+d |
2020-03-23 |
| Koki Holdings–Eppendorf: investment, 202003– acquisition €na of Koki’s Centrifuge + Processing business by Eppendorf from KKR |
2020-03-19 |
| BMS–Oxford BioMedica: lentiviral vector technology, 202003– license non-excl + supply agreem LentiVector for CAR-T + TCR-T therapeutics of Juno |
2020-03-18 |
| OncoOne–SEVERAL: investment, 202003 financing round Series A €13m investors include FFG + AWS + two family offices |
2020-03-18 |
| OncoOne–Trophic Communications: public relations, 202003 service existent by Trophic Communications |
2020-03-18 |
| Immatics–Arya Sciences: investment, 202003 reverse merger resulting in Nasdaq-listing of Immatics + $148m cash held by Arya |
2020-03-17 |
| Immatics–SEVERAL: investment, 202003 common stock PIPE $104m led by Perceptive Advisors |
2020-03-17 |
| Pfizer–BioNTech: mRNA-based vaccines, 202003– collab development of COVID-19 vaccine |
2020-03-17 |
| BioNTech–Fosun: investment, 202003 equity investment €44m for 1.58m ordinary shares by Fosun Pharma as part of COVID-19 vaccine collab |
2020-03-16 |
| Fosun–BioNTech: mRNA-based vaccines, 202003– collab up to €120m + profit sharing development of COVID-19 vaccine in China with Fosun Pharma |
2020-03-16 |
| Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS |
2020-03-10 |
| Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF |
2020-03-10 |
| Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical |
2020-03-10 |
| Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF |
2020-03-10 |
| iAtros–Bavaria (govt): investment, 202003 seed financing round totalling €2m incl investor Bayern Kapital |
2020-03-09 |
| iAtros–High-Tech Gründerfonds: investment, 202003 seed financing round totalling €2m incl investor HTGF |
2020-03-09 |
| iAtros–OTHER: investment, 202003 seed financing round totalling €2m incl several business angels |
2020-03-09 |
| iAtros–SEVERAL: investment, 202003 seed financing round €2m from HTGF + Bayern Kapital + several business angels |
2020-03-09 |
| Numab–MacDougall Biomedical Communications: public relations, 202003 service existent by MacDougall |
2020-03-09 |
| Qiagen–Barclays: financial services, 202003 supply service Barclays Bank plc is financial advisor w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–De Brauw Blackstone Westbroek: legal services, 202003 supply service De Brauw BW NV is legal counsel w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–Goldman Sachs: financial services, 202003 supply service Goldman Sachs Intl is lead financial advisor w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–Linklaters: legal services, 202003 supply service Linklaters LLP is legal counsel w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–Mintz Levin Cohn: legal services, 202003 supply service Mintz Levin Cohn FGP is legal counsel w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–Thermo Fisher: investment, 202003– acquisition €9.14b cash tender offer at €39/share ANNOUNCED |
2020-03-03 |
| Thermo Fisher–JPMorgan Chase: financial services, 202003 supply service JP Morgan Securities LLC is financial advisor w regard to Qiagen acquisition |
2020-03-03 |
| Thermo Fisher–Morgan Stanley: financial services, 202003 supply service Morgan Stanley & Co LLC is financial advisor w regard to Qiagen acquisition |
2020-03-03 |
| Thermo Fisher–Wachtel Lipton Rosen & Katz: legal services, 202003 legal council to Thermo Fisher with regard to acquisition of Qiagen |
2020-03-03 |
| Sterling Pharma Solutions–Thermo Fisher: LC system, 202003 supply early customer for Vanquish Core HPLC System |
2020-03-02 |
| Boehringer–Trutino Biosciences: cancer immunotherapy, 202002– collab research + ww excl license to develop up to 3 candidates using ODC technology |
2020-02-27 |
| Centogene–Coulter Partners: recruitment services, 202002 supply service placement of Philip Lambert as CSO at Centogen based in US |
2020-02-26 |
| FinnGen–GSK: genomics, 202002 collab existent GSK is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Merck (US): genomics, 202002 collab existent MSD is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Pfizer: genomics, 202002 collab existent Pfizer is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Roche: genomics, 202002 collab existent Genentech is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Sanofi: genomics, 202002 collab existent Sanofi is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| ImmunOs Therapeutics–Minapharm: biopharma production, 202002– supply €na support developm using DirectedLuck + large-scale production by ProBioGen |
2020-02-25 |
| Roche–Bicycle Therapeutics: small-molecule drugs, 202002– collab strategic $30m upfront + up to $1.7b r+d of bicycle peptides for cancer Genentech |
2020-02-25 |
| Scipio Bioscience–BPCE: investment, 202002 financing round Series A totalling €6m incl existing + co-investor Seventure Partners Quadrivium 1 Fund |
2020-02-25 |
| Scipio Bioscience–High-Tech Gründerfonds: investment, 202002 financing round Series A totalling €6m incl existing + co-investor HTGF |
2020-02-25 |
| Scipio Bioscience–Merck (DE): investment, 202002 financing round Series A totalling €6m incl lead investor M Ventures |
2020-02-25 |
| Scipio Bioscience–SEVERAL: investment, 202002 financing round Series A €6m led by M Ventures |
2020-02-25 |
| Scipio Bioscience–Verve Capital Partners: investment, 202002 financing round Series A totalling €6m incl new + co-investor investiere |
2020-02-25 |
| GSK–Immatics: cell therapy, 202002– strategic collab $45m upfront + $1.1b milestones for first two TCR therapeutics programmes + royalties |
2020-02-20 |
| OncoDNA–SEVERAL: investment, 202002 financing round Series B €19m co-led by Vesalius Biocapital III + Swisscanto Invest |
2020-02-14 |
| OncoDNA–Vesalius Biocapital: investment, 202002 financing round Series B totalling €19m incl co-lead investor Vesalius Biocapital III |
2020-02-14 |
| OncoDNA–Zürcher Kantonalbank: investment, 202002 financing round Series B totalling €19m incl co-lead investor Swisscanto Invest by ZKB |
2020-02-14 |
| NanoPin Technologies–Thermo Fisher: mass spectrometry, 202002– collab developm LC-MS-based workflows for blood-based infectious disease diagnostics |
2020-02-13 |
| Azafaros–BioMedPartners: investment, 202002 financing round Series A totalling €25m incl co-investor BioMedPartners |
2020-02-06 |
| Azafaros–SEVERAL: investment, 202002 financing round Series A €25m led by Forbion with participation from BioMedPartners + BGV |
2020-02-06 |
| Azafaros–Trophic Communications: public relations, 202002 service existent by Trophic Communications |
2020-02-06 |
| PentixaPharm–SEVERAL: investment, 202002 financing round Series A €15m led by ELSA Eckert Life Science Accelerator |
2020-02-06 |
| Aimmune Therapeutics–Nestlé: investment, 202002 equity investment $200m by Nestlé Health Science results in 19.9% common stock + 25.6% fully diluted |
2020-02-05 |
| MaaT Pharma–Biocodex: investment, 202002 financing round Series B totalling €18m incl existing investor Biocodex |
2020-02-05 |
| MaaT Pharma–BPCE: investment, 202002 financing round Series B totalling €18m incl existing investor Seventure Partners |
2020-02-05 |
| MaaT Pharma–Crédit Mutuel-CIC: investment, 202002 financing round Series B totalling €18m incl existing investor Crédit Mutuel Innovation |
2020-02-05 |
| MaaT Pharma–SEVERAL: investment, 202002 financing round Series B €18m with SymBiosis + Seventure + Crédit Mutuel Innovation + Biocodex et al. |
2020-02-05 |
| MaaT Pharma–SymBiosis LLC: investment, 202002 financing round Series B totalling €18m incl new investor SymBiosis LLC |
2020-02-05 |
| MaaT Pharma–Trophic Communications: public relations, 202002 service existent by Trophic Communications |
2020-02-05 |
| Novartis–BenchSci: AI-based reagent selection software, 202002– supply expansion Novartis to deploy new AI-Assited Reagent Selection product |
2020-02-04 |
| Catalent–SEVERAL: investment, 202002 underwritten public offering $500m+$75m with approx $330m intented to finance MaSTherCell acquisition |
2020-02-03 |
| Stalicla–SEVERAL: investment, 202002 financing round Series A 2nd closing of CHF7.7m ($8m) bringing total raised to $18.4m |
2020-02-03 |
| Valneva–Deerfield: credit, 202002–202601 debt financing totalling $60m + optional $25m facility from Deerfield Management + OrbiMed |
2020-02-03 |
| Valneva–OrbiMed: credit, 202002–202601 debt financing totalling $60m + optional $25m facility from Deerfield Management + OrbiMed |
2020-02-03 |
| Valneva–SEVERAL: credit, 202002–202601 debt financing $60m + optional $25m facility from Deerfield Management + OrbiMed |
2020-02-03 |
| Temedica–Public Performance: public relations, 202002 service existent by Public Performance |
2020-02-01 |
| GeNeuro–Mérieux: investment, 202001 private placement totalling €17.5m incl €7.5m from existing investor GNEH SAS now largest shareholder with 36.46% |
2020-01-31 |
| GeNeuro–SEVERAL: investment, 202001 private placement €17.5m with 5.93m new shares at €2.95/share incl existent investor GNEH SAS |
2020-01-31 |
| Univ Kyoto–Miltenyi Biotec: cell sorting system, 202001 supply existent MACS GMP Tyto Cartrige + MACSquant Tyto Cell Sorter to CiRO as early customer |
2020-01-30 |
| Quench Bio–SEVERAL: investment, 202001 financing round Series A $50m led by RA Capital + incl AbbVie Ventures + Atlas Venture + Arix Bioscience |
2020-01-27 |
| iOnctura–SEVERAL: investment, 202001 financing round Series A €15m led by Inkef Capital + co-led by VI Partners |
2020-01-23 |
| HepaRegenix–SEVERAL: investment, 202001 financing round Series B €11m with BIVF + Novo Holdings + HTGF + Coparion + Ascenion |
2020-01-21 |
| BioNTech–Covington & Burling: legal services, 202001 supply service legal counsel with regard to merger acquisition of Neon Therapeutics |
2020-01-16 |
| Neon Therapeutics–BioNTech: investment, 202001–acquisition merger $67m by BioNTech in all-stock transaction with 0.063 ADSs/share = $2.18/share |
2020-01-16 |
| Neon Therapeutics–Goodwin Procter: legal services, 202001 supply service legal counsel with regard to merger acquisition by BioNTech |
2020-01-16 |
| Neon Therapeutics–Ondra Partners: financial services, 202001 supply service excl financial advisor with regard to merger acquisition by BioNTech |
2020-01-16 |
| Danaher–Sophia Genetics: genomic technologies, 202001– collab ww expansion IDT NGS enrichment products with Sophia Genetics DDM for clinical research |
2020-01-15 |
| Lunaphore–Alpana Ventures: investment, 202001 financing round Series C totalling CHF23m incl existing + co-investor Alpana Ventures |
2020-01-15 |
| Lunaphore–Occident Group: investment, 202001 financing round Series C totalling CHF23m incl existing + co-investor Occident |
2020-01-15 |
| Lunaphore–PHC: investment, 202001 financing round Series C totalling CHF23m incl new + lead investor PHC Holdings Corp |
2020-01-15 |
| Lunaphore–Redalpine: investment, 202001 financing round Series C totalling CHF23m incl existing + co-investor Redalpine Venture Partners |
2020-01-15 |
| Lunaphore–SEVERAL: investment, 202001 financing round Series C CHF23m led by PHC Holdings Corp |
2020-01-15 |
| Temedica–Gruner + Jahr: investment, 202001 financing round Series B totalling €17m incl existing + co-investor G+J Digital Ventures |
2020-01-14 |
| Temedica–MIG Fonds: investment, 202001 financing round Series B totalling €17m incl co-lead investor MIG Funds |
2020-01-14 |
| Temedica–PERSON: investment, 202001 financing round Series B totalling €17m incl existing + co-investor Bernd Wendeln |
2020-01-14 |
| Temedica–Salvia: investment, 202001 financing round Series B totalling €17m incl co-lead investor Salvia |
2020-01-14 |
| Temedica–SEVERAL: investment, 202001 financing round Series B €17m led by MIG Funds + Santo VC + Salvia |
2020-01-14 |
| Temedica–Strüngmann Group: investment, 202001 financing round Series B totalling €17m incl co-lead investor Santo Venture Capital |
2020-01-14 |
| Amgen–Qiagen: molecular companion diagnostics, 202002– collab developm KRAS G12C CDx for AMG 510 in NSCLC |
2020-01-13 |
| Andrew Alliance–Waters: investment, 202001 acquisition by existent investor Waters |
2020-01-13 |
| Daiichi Sankyo–ERS Genomics: CRISPR technology, 202001– license ww excl €na for internal r+d |
2020-01-13 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
